Angus M.S. Toland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angus M.S. Toland has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Araz Marachelian
Department of Pediatrics, Keck School of Medicine, University of Southern California, Children's Hospital of Los Angeles, Los Angeles, CA
5 shared publications - Arlene Naranjo
Department of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL
5 shared publications - Bill Chiu
Division of Pediatric Surgery, Department of Surgery, Stanford University, Palo Alto, USA
5 shared publications - Elizabeth Wagner
COG Biospecimen Bank, Biopathology Center, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio
5 shared publications - Florette K. Hazard
Department of Pathology, Stanford University School of Medicine, Stanford, California
5 shared publications - Hiroyuki Shimada
Department of Pathology, Stanford University School of Medicine, Palo Alto, CA
5 shared publications
Latest Publications
- 16 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (10) , 2435-2448
High-grade astrocytoma with piloid features: A clinical and genomic analysis of prognostic factors using a large cohort
Background: High-grade astrocytoma with piloid features (HGAP) is a recently defined tumor type that is not well understood. Prognostic factors of clinical outcomes are not well established. Methods: Methylation profiling was performed on tumor samples, many at the National Cancer Institute (NCI) Laboratory of Pathology, and others from publicly available sources. Methylation classifier scores of ≥0.90 to the HGAP class on the NCI-Bethesda classifier version 3 were included. Clinical features were collected from the medical record. Survival analyses were performed using the Kaplan-Meier and Cox-proportional hazards methods. Results: The cohort comprised 421 patients. There were high rates of ATRX alteration (62%), CDKN2A/B homozygous loss (78%) and MGMT promoter methylation (53%). MAPK alterations were identified in 74% of evaluable samples. The median age was 46 years, and posterior fossa location was predominant (52%). The median overall survival was 88 months. Older age (P = .01) and the presence of an ATRX alteration (P = .04) were found to be negative prognostic factors. The presence of cystic features on magnetic resonance imaging (MRI) was found to be favorably prognostic (P = .01). Factors that were not significantly associated with prognosis included histologic high-grade features, CDKN2A/B homozygous deletion, MGMT promoter methylation, extent of resection, and presence of NF1 syndrome. Conclusions: This large cohort establishes relative frequencies of several important markers. Additionally, older age, the presence of an ATRX alteration, and cystic features on MRI were found to be prognostic. Our work may aid in optimizing treatment regimens for patients with this tumor type.
- 16 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (10) , 2435-2448
High-grade astrocytoma with piloid features: A clinical and genomic analysis of prognostic factors using a large cohort
Background: High-grade astrocytoma with piloid features (HGAP) is a recently defined tumor type that is not well understood. Prognostic factors of clinical outcomes are not well established. Methods: Methylation profiling was performed on tumor samples, many at the National Cancer Institute (NCI) Laboratory of Pathology, and others from publicly available sources. Methylation classifier scores of ≥0.90 to the HGAP class on the NCI-Bethesda classifier version 3 were included. Clinical features were collected from the medical record. Survival analyses were performed using the Kaplan-Meier and Cox-proportional hazards methods. Results: The cohort comprised 421 patients. There were high rates of ATRX alteration (62%), CDKN2A/B homozygous loss (78%) and MGMT promoter methylation (53%). MAPK alterations were identified in 74% of evaluable samples. The median age was 46 years, and posterior fossa location was predominant (52%). The median overall survival was 88 months. Older age (P = .01) and the presence of an ATRX alteration (P = .04) were found to be negative prognostic factors. The presence of cystic features on magnetic resonance imaging (MRI) was found to be favorably prognostic (P = .01). Factors that were not significantly associated with prognosis included histologic high-grade features, CDKN2A/B homozygous deletion, MGMT promoter methylation, extent of resection, and presence of NF1 syndrome. Conclusions: This large cohort establishes relative frequencies of several important markers. Additionally, older age, the presence of an ATRX alteration, and cystic features on MRI were found to be prognostic. Our work may aid in optimizing treatment regimens for patients with this tumor type.
- Open Access
- 7 January 2026
- Published by Wiley in Case Reports in Pathology
- Vol. 2026 (1)
Chronic Basal Ganglia Infarction With PCR‐Identified Paeniclostridium sordellii : A Rare Neuropathological Case Report
Background: Within 1 month of diagnosis, 40% of patients with positive blood cultures will develop CNS complications. Rare pathogens, that is, Paeniclostridium sordellii , pose diagnostic challenges due to atypical presentations and detection difficulties. Case Presentation: A 67‐year‐old man presented with metabolic encephalopathy and diabetes insipidus. Imaging showed bilateral basal ganglia abnormalities and an enhancing lesion near the anterior commissure, suspicious for neoplasm. Postmortem findings included reactive gliosis, atypical lymphocytic inflammation, and polyclonal plasma cells. NGS performed at the University of Washington confirmed P. sordellii infection. Neuropathologic Findings: The gross and histologic examination showed mild hydrocephalus, right hippocampal atrophy, and anterior commissure–centric inflammation. Vascular congestion, arteriosclerosis with microthrombi, and oligodendrocyte loss were present without hemorrhage. Differential Diagnosis: Hemophagocytic lymphohistiocytosis and CNS lymphoma were considered but ruled out microscopically. Conclusion: This case highlights the importance of considering P. sordellii in CNS inflammatory lesions and demonstrates the utility of molecular diagnostics in negative cultures.
- 7 January 2026
- Published by Wiley in Case Reports in Pathology
- Vol. 2026 (1)
Open AccessChronic Basal Ganglia Infarction With PCR‐Identified Paeniclostridium sordellii : A Rare Neuropathological Case Report
Background: Within 1 month of diagnosis, 40% of patients with positive blood cultures will develop CNS complications. Rare pathogens, that is, Paeniclostridium sordellii , pose diagnostic challenges due to atypical presentations and detection difficulties. Case Presentation: A 67‐year‐old man presented with metabolic encephalopathy and diabetes insipidus. Imaging showed bilateral basal ganglia abnormalities and an enhancing lesion near the anterior commissure, suspicious for neoplasm. Postmortem findings included reactive gliosis, atypical lymphocytic inflammation, and polyclonal plasma cells. NGS performed at the University of Washington confirmed P. sordellii infection. Neuropathologic Findings: The gross and histologic examination showed mild hydrocephalus, right hippocampal atrophy, and anterior commissure–centric inflammation. Vascular congestion, arteriosclerosis with microthrombi, and oligodendrocyte loss were present without hemorrhage. Differential Diagnosis: Hemophagocytic lymphohistiocytosis and CNS lymphoma were considered but ruled out microscopically. Conclusion: This case highlights the importance of considering P. sordellii in CNS inflammatory lesions and demonstrates the utility of molecular diagnostics in negative cultures.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Statistical Framework of INPC-Risk Grouping System
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Statistical Framework of INPC-Risk Grouping System
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Purpose:Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC).Experimental Design:The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors.Results:This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC.Conclusions:The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Purpose:Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC).Experimental Design:The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors.Results:This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC.Conclusions:The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
International Neuroblastoma Pathology Classification.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
International Neuroblastoma Pathology Classification.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Children’s Oncology Group Revised Neuroblastoma Risk Classification.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Children’s Oncology Group Revised Neuroblastoma Risk Classification.
- 27 October 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (1) , 127-134
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Purpose: Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC). Experimental Design: The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors. Results: This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC. Conclusions: The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.
- 27 October 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (1) , 127-134
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Purpose: Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC). Experimental Design: The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors. Results: This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC. Conclusions: The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.